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Abstract
The sympatho-adrenergic system is highly involved in regulating sleep, wake and arousal states, and abnormalities in this
system are regarded as a key factor in the development and progression of arterial hypertension. While hypertension is
associated with a hyperadrenergic state during wakefulness, the effect of hypertension on plasma-catecholamine levels
during sleep is not yet known. Twelve young participants with newly diagnosed, untreated hypertension and twelve
healthy controls slept for 7 hours in the sleep laboratory. Before and after sleep, subjects rested in a supine position for 3-h
periods of wakefulness. We sampled blood at a fast rate (1/10 min) and monitored blood pressure and heart rate
continuously. We show that plasma NE and E levels did not differ between hypertensives and normotensive during sleep as
well as before and after sleep. Blood pressure was higher in hypertensives, reaching the largest group difference in the
morning after sleep. Unlike in the normotensives, in the hypertensive participants the morning rise in blood pressure did
not correlate with the rise in catecholamine levels at awakening. Our results suggest that hypertension in its early stages is
not associated with a strong hyperadrenergic state during sleep. In showing a diminished control of blood pressure through
sympatho-adrenergic signals in hypertensive participants, our data point towards a possible involvement of dysfunctional
sleep-related blood pressure regulation in the development of hypertension.
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Introduction
The sympathetic system exerts a key role in homeostatic blood
pressure control. It has been hypothesized that an abnormality in
sympathetic control of the cardiovascular system participates in
the development and progression of hypertension ([1], for a
review). This ‘‘neuroadrenergic hypothesis of hypertension’’ was
established in patients suffering either from secondary end-organ
damage of heart and kidneys or from comorbidities that induce
sympatho-excitation like the metabolic syndrome or sleep-related
breathing disorders. Indeed, also several studies have provided
evidence that even in young hypertensives plasma levels of
norepinephrine (NE) as well as other markers of sympathetic drive,
are increased [1–4]. However, whereas these studies were
conducted during active wakefulness, the effect of hypertension
on plasma NE levels during nocturnal sleep is still unknown.
Recent studies have renewed interest in the importance of sleep-
related sympathetic nervous processes for the pathophysiology of
hypertension. Normal nocturnal sleep is characterized by a
marked decrease in sympathetic activity and blood pressure, with
these processes also affecting sympathetic regulation of blood
pressure during subsequent daytime wakefulness [5]. Moreover,
there is growing evidence pointing to a significant contribution of
sleep and sleep-related control of blood pressure to the
development of hypertension [6–8]. In addition, epidemiological
studies have consistently associated short sleep duration and poor
sleep quality with higher blood pressure, and these sleep
parameters readily predicted increases in blood pressure over the
next 5 years [9,10]. Conversely, chronic sleep disturbances in the
case of sleep apnea-hyponea are strongly linked to an increased
risk of hypertension [11] and experimental sleep deprivation
increases blood pressure in both animals and humans (see [12], for
a review). However, the underlying processes remain to be
elucidated. One important factor might be related to alterations of
the sympatho-adrenergic activity during sleep.
Therefore, in the present study, we investigated whether
hypertension alters catecholaminergic activity during sleep. Based
on the neuroadrenergic hypothesis of hypertension [1], we
predicted that sympatho-adrenergic activity should be elevated
during sleep already in early hypertension. To avoid confounding
effects of variables like obesity, sleep fragmentation and sleep
apnea-hyponea, we only included young, otherwise healthy
participants with newly diagnosed, untreated primary hyperten-
sion in our experimental group. Twelve normotensive and the
twelve young hypertensive participants slept a regular 7-h period
of nocturnal sleep in the sleep laboratory. Subjects remained in a
horizontal position for 3-h periods of wakefulness before and after
sleep. Blood pressure and heart rate were recorded continuously,
and plasma catecholamines were sampled repeatedly at a fast rate
(every 10 min) in order to correlate sympathoadrenergic activity
with sleep stages. The design allowed us to investigate whether
hypertension affected plasma levels of NE and E during sleep
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21292compared to wakefulness before and after sleep as well as
depending on the sleep stage (NonREM vs. REM).
Methods
Subjects
12 normotensive men (26.461.7 years) and 12 men with newly
diagnosed untreated primary hypertension (26.363.5 years)
participated in the experiments. All participants were students at
the University of Lu ¨beck and were paid for participation. Subjects
were healthy, non-smoking, did not report any sleep disturbances,
and had not worked on night-shift for at least 8 weeks. The study
was approved by the local ethics committee and all participants
gave written informed consent.
Student subjects were recruited during a 6-months period on
the campus of the University of Lu ¨beck (by advertising in the
students’ cafeteria, lectures etc.). Particularly those with a positive
family history of hypertension were addressed in the advertise-
ment. Altogether 180 male students were evaluated over a period
of 4 weeks before 12 hypertensive subjects and 12 controls were
found. The normotensive control subjects were recruited from the
same group. A comprehensive medical history, and physical
examination and a laboratory screening (creatinine, electrolytes,
urinalysis) confirmed that all included subjects were otherwise
healthy. Additionally, all subjects were non-smoking, did not
report any sleep disturbances, and had not worked on night-shift
for at least 8 weeks prior to participation. The study was approved
by the local ethics committee and all participants gave written
informed consent.
The hypertensive men were selected on the basis of repeated
oscillometric blood pressure measurements (Welsh AllynH). This
‘‘Vital signs’’ monitor has been validated previously [13]. The
inclusion criterion was a systolic blood pressure higher than
140 mmHg and a diastolic blood pressure higher than 90 mmHg
on three subsequent measurements (each measurement at least
2 min apart) obtained while the subject was sitting after a 10 min
period of rest. Hypertensive and normotensive subjects were
matched regarding age and body mass index (see Table 1 for
anthropometric data). There were no differences between the
normotensive and early hypertensive groups in body mass index
(22.8666.6 versus 23.9569.7, P.0.75), reported daily physical
activity and sleep parameters on the adaptation nights (all P.0.3).
In the pre-experimental interviews subjects of the early hyperten-
sive group expressed slightly more often hints towards a family
history of hypertension. Data of normotensive participants were
partly published elsewhere [14].
Procedure
Subjects were adjusted to the experimental setting by spending
at least one prior night under conditions of the experiment
including standard polysomnographic recordings and the place-
ment of catheters for blood collection. The men were also adjusted
to continuous blood pressure recording measured photoplethys-
mographically at the finger using the Finapres technique (Ohmeda
Monitoring Systems, Englewood, CO; [15]). While this method
allows continuous non-invasive blood pressure monitoring during
prolonged intervals, absolute values of blood pressure may differ
from those obtained by oscillometric measurements. The mea-
surement required the fixation of the arm and finger used to attach
the pressure cuff, and in turn a relatively constant sleeping position
either on the back or front. For adapting the subject to this
procedure, during two nights at home and during an additional
night at the sleep laboratory (preceding the adaptation night) he
slept in the same body position as during the experiments with one
arm fixated to the bed frame. Although habituation to arm fixation
may not have been completed after the fourth night, sleep
recordings on the experimental night as well as interviews with the
subjects did not reveal any hint at a substantial sleep disturbance
introduced by this procedure. For these adaption nights, it was
carefully controlled that there were no increases in signs of sleep
fragmentation, arousals or apnoeas during sleep, and there were
also no differences in these signs between the experimental groups,
i.e., all participants exhibited healthy normal sleep without any
signs of increased arousals or apnoea. Although this is a limiting
factor of our study, we did not directly monitor blood oxygen
levels to avoid additional disturbing effects on sleep in the
laboratory, and because we did not detect any hints for the
presence of sleep apneas in any of our subjects based on the pre-
experimental interviews and the recordings in the adaptation
nights.
During the wake periods preceding experimental sleep periods,
subjects had to abstain from coffee, black tea and alcoholic drinks,
but to maintain their normal diet. They had eaten a regular meal
2 h before recordings started. They were not allowed to take any
naps during the wake periods preceding experimental epochs.
Subjects arrived at the laboratory ,1 h before the start of
recordings, to prepare standard polysomnography, blood sampling
and recordings of blood pressure.
Recordings started at 20:00 h. After a 30-min phase of
habituation, subjects spent awake for the 3-h interval between
20:30 and 23:30 h. Then, lights were turned off to enable sleep for
7 h, until 06:30 h, when they were gently awoken. Subjects stayed
awake for another 3-h period between 06:30 and 09:30 h. During
the periods of wakefulness, they were allowed to read magazines or
to talk to the experimenters. Subjects remained in a supine
position throughout the entire recording epoch between 20:00 and
09:30 h.
Standard polysomnographic recordings [16] included continu-
ous monitoring of electroencephalogram, electrooculogram and
electromyogram. For blood sampling, a catheter was inserted into
a forearm vein and connected to a long thin plastic tube that
enabled blood collection from an adjacent room without
disturbing the subject’s sleep. Blood was sampled every 10 min
throughout the recording epochs. To prevent clotting and to
substitute removed blood volume saline solution was infused slowly
throughout the recording epoch totaling a volume of ,300 ml.
Data Reduction and Statistical Analyses
Polysomnographic recordings were scored offline, independent-
ly by two experienced experimenters, according to the standard
criteria [16]. Subsequent 30-s epochs of recordings were scored
Table 1. Subjects’ characteristics.
Normotensives Hypertensives
Age (yrs) 26.465.9 26.3612.1
Body mass index (kg/m
2) 22.8666.6 23.9569.7
Systolic blood pressure
(mmHg)
125.1627.7 156.9650.9*
Diastolic blood pressure
(mmHg)
72.6625.3 90.6629.8*
Age, body mass index, diastolic and systolic blood pressure of the 12
normotensive and 12 hypertensive subjects (means 6 standard deviation).
Blood pressure values are means of three consecutive oscillometric
measurements in sitting subjects after a rest of 10 min. *p,0.05 compared to
the respective blood pressure values of normotensives.
doi:10.1371/journal.pone.0021292.t001
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stages 1, 2 (S1–S2), or slow-wave-sleep (SWS, defined by the sum
of S3–4), and REM sleep. For each night, total sleep time (in min)
and the percentage of total sleep time spent in the different sleep
stages were determined. Sleep onset latency was defined by the
first epoch of S1 sleep followed by S2 sleep and determined with
reference to the time of lights off. Latency of S2 sleep, SWS, and
REM sleep was calculated with reference to sleep onset.
For determination of plasma concentrations of NE and E, blood
samples were centrifuged immediately after collection, and plasma
was stored at 280uC until assay. NE and E were determined by
standard high performance liquid chromatography with subse-
quent electrochemical detection (Chromsystems Instruments and
Chemicals, Munich Germany [17]). The sensitivity was 6.48 pg/
ml for E and 6.02 pg/ml for NE. The interassay coefficients of
variation were 5.6% and 6.1% for E and NE, respectively.
Intraassay coefficients of variation were confirmed by measuring a
small fraction of sample from this study in duplicate in the same
assay. Because blood was sampled every 10 minutes during the
entire experimental procedure (total duration approx. 13 h),
approximately 78 samples were obtained for each individual,
providing altogether a reliable basis for hormonal measurements.
Average values were calculated of plasma NE and E
concentrations, and of heart rate, systolic and diastolic blood
pressure for the 3-hour wake periods before (‘pre-wake’ period)
and after sleep (‘post-wake’ period) and for the time in each sleep
stage. Calculations were based on plasma concentrations of NE
and E for subsequent 30-s intervals as determined by linear
interpolation.
Effects were statistically evaluated using analyses of variance
(ANOVA) including the between-subject factors ’group’ (hyper-
tensives vs. normotensives) and the repeated measures factor
‘sleep/wake’ periods (pre-wake, sleep, post-wake) or for ‘sleep
stage’ (intermittent wake time, S1, S2, SWS, REM sleep). No data
from any variable significantly deviated from the normal
distribution as indicated by Kolomogorov-Smirnov Tests. To
account for violations of the sphericity-assumption, degrees of
freedom were adjusted using the Greenhouse-Geisser procedure in
SPSS 16.0. Significant main effects of sleep/wake or sleep stage
were specified by planned pair-wise contrasts with reference to
sleep or REM sleep. Significant interactions (group x sleep/wake
or group x sleep stage) were further explored using paired t-tests
comparing mean values in hypertensives and normotensives for
the different sleep or wake stages. For post-hoc testing, Fishers’s
least significant difference (LSD) correction was applied to account
for increased error probability due to multiple comparisons. A P-
value ,0.05 was considered significant.
Results
Characteristics of sleep
Nocturnal sleep in hypertensive men did not differ from sleep in
the normotensive group (all P.0.1; Table 2).
Effects of Sleep on Catecholamine Concentrations
In contrast to the notion of an sympatho-adrenergic over
activation in hypertension, we did not observe any significant
group differences between average levels of NE or E during the pre-
wake, sleep and post-wake periods, respectively (main effect group
NE: F(1,22) =1.1, E: F(1,22) =0.0; both P.0.30). Generally, the
concentrations of NE and E were significantly lower during sleep
than during wakefulness (main effect sleep/wake NE: F(2,44)
=23.5, p,0.001; E: F(2,44) =6.1, P,0.01; Figure 1), and, these
general effects were similarly observed in hypertensives as well as
normotensives as indicated by non-significant interaction terms
(interaction group * sleep/wake for NE and E concentrations: both
P.0.28). In an analysis of all succeeding time points of blood
sampling during the periods of interest (Figure 2), NE concentra-
tions were revealed to be even significantly lower in the
hypertensives as compared to the normotensive controls during
most of the pre-sleep wake interval. During sleep, hypertensives
still exibited lower NE levels on a descriptive level, although these
differences were non-significant (see Figure 2). During sleep,
plasma catecholamine concentrations distinctly varied depending
on the sleep stage, with linearly decreasing values as sleep deepens,
reaching minimal levels during REM sleep (main effect of stage for
NE and E concentrations, respectively: F(4,88) =4.95; P,0.01 and
F(4,88) =7.36; P,0.001). The effect of sleep stages on NE and E
concentration did not differ between hypertensives vs. normoten-
sives (interaction group * sleep stage: F(4,88) =2.12; P.0.10 and
F(4,88) =0.45; P.0.50).
To further evaluate our non-significant findings, we conducted
post hoc power analyses using the software G*Power [18]. With
regard to the comparison of average NE and E levels between
hyper- and normotensives, we can safely exclude large effect sizes
(f$0.6 or d$1.2) with a probability of 1-b.80%. However, we
would like to emphasize that descriptively, the values for E and NE
were even lower in early hypertensives as compared to
normotensives. Thus, the descriptive effect was in the opposite
direction (sometimes even significantly, see Figure 2). An increase
in statistical power by increasing the number of participants would
therefore detect a hypoadrenergic state rather than a hypera-
drenergic state in our study. With regard to the interaction effects
(group x sleep/wake and group x sleep stages, respectively), we can
safely exclude small to medium effect sizes (f$0.2 or d$0.4) with a
probability of 1-b.80%.
Effects of Sleep on Cardiovascular Parameters
Overall, systolic and diastolic blood pressure during pre-wake,
sleep and post-wake periods were significantly higher in hyper-
tensive than normotensive participants (12962.5/70.36
1.4 mmHg vs. 119.762.5/65.361.4 mmHg, F(1,22)=7.0 and
6.1, respectively, both P,0.03). In addition, blood pressure was
generally lower during sleep as compared to wakefulness in both
groups, indicating that in both groups some sleep-related blood
Table 2. Sleep characteristics in normotensive or
hypertensive subjects (mean6s.d.).*
Normotensives Hypertensives
Total Sleep Time (min) 398.5 6 30.1 397.3 6 24.1
Sleep Stages
W %) 5.9 6 5.6 9.6 6 8.6
S1(%) 12.4 6 8.1 10.6 6 5.7
S2 (%) 44.8 6 11.6 43.8 6 9.4
SWS (%) 16.1 6 4.4 18.6 6 5.3
REM (%) 20.7 6 4.8 17.4 6 4.6
Sleep onset latency (min) 23.0 6 30.1 23.7 6 24.1
S2 latency (min) 5.9 6 2.5 6.0 6 5.0
SWS latency (min) 28.6 6 25.9 23.6 6 23.6
REM latency (min) 70.0 6 18.9 108.8 6 50.2
*There were no significant differences in sleep parameters between
normotensive and hypertensive subjects.
doi:10.1371/journal.pone.0021292.t002
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sleep vs. wakefulness on blood pressure differed between
hypertensives and healthy controls: While the difference in systolic
blood pressure between both groups was small during sleep
(118.763.5 mmHg vs. 109.661.9 mmHg, P,0.04) and non-
significant during the wake period before sleep (pre-wake period:
133.263.2 mmHg vs. 129.062.8 mmHg, P.0.28), hypertensives
demonstrated highly significant increases in systolic blood pressure
during wakefulness after sleep (135.063.3 mmHg vs.
120.563.0 mmHg, P,0.005; interaction group * sleep/wake:
F(2,44) =3.7, P,0.04, Figure 1). A similar pattern was observed for
diastolic blood pressure, with the highest differences between
hypertensives and normotensives occurring in the morning after
sleep (74.362.0 mmHg vs. 65.6 mmHg, P,0.004; interaction
group * sleep/wake: F(2,44) =5.6, P,0.01).
Heart rate was also generally lower during sleep as compared to
wakefulness (F(2,44)=27.2; P,0.001) in both groups. During sleep,
heart rate tended to be lower in hypertensives (Figure 2), although
the interaction between hyper- and normotensive participants did
not reach significance (main effect and interaction: both P.0.16).
There was also an influence of the different sleep stages on
systolic and diastolic blood pressure as well as on heart rate (F(4,88)
=16.8, 13.8, and 27.4, respectively, all P,0.001). Consistent with
our previous report [14], systolic and diastolic blood pressure as
well as heart rate decreased with increasing depth of NonREM
sleep and increased during REM sleep to levels comparable with
those during intermittent wake periods. We did not observe any
modulating influence of hypertension vs. normotension on this
sleep-stage specific pattern of cardiovascular parameters (interac-
tion group * sleep stage: all P.0.50).
Relation between the morning increase in blood
pressure and catecholamine concentrations
Because the largest difference between hypertensives and
normotensives in blood pressure occurred in the morning after
sleep, we further analyzed the relation between this increase and
Figure 1. Means ± S.E.M. Norepinephrine and Epinephrine plasma concentrations, blood pressure (BP) and heart rate during 3-h
periods of wakefulness prior to (pre-wake) and after sleep (post-wake), and during the 7-h sleep period for hypertensives (white)
and healthy normotensive controls. *P,0.05; **P,0.01, for pairwise comparisons between hyper- and normotensives.
doi:10.1371/journal.pone.0021292.g001
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difference between the mean of the post-wake period and the mean
of the preceding sleep period. As indicated by the above reported
analyses, for systolic and diastolic blood pressure this morning rise
was on average higher in the hypertensives than in the
normotensives (Systolic: +16.362.7 mmHg vs. +10.962.2 mmHg;
Diastolic: +9.061.6 mmHg vs. +4.561.4 mmHg; P,0.05), where-
as the corresponding rise in E and NE levels did not significantly
differ between the groups (NE: +34.265.0 pg/ml vs. +30.56
5.4 pg/ml; P=0.61; E: +13.765.3 pg/ml vs. +5.561.1 pg/ml;
P=0.16). Correlation analyses in the normotensive group revealed,
as expected (e.g., [14,19]), that the morning rise in systolic and
diastolic blood pressure was strongly correlated with the morning
rise in E levels (r=0.60 and 0.68, respectively, for systolic and
diastolic blood pressure, both P,0.04, see Figure 3). Similarly
positive but non-significant correlations were observed with the
morning rise in NE values (systolic BP: r=0.55, P=0.07; diastolic:
r=0.38, P=0.23). In striking contrast, hypertensives exhibited no
positive correlation between the morning rise in blood pressure and
catecholamine levels, neither for E (r=20.30 and 20.16; both
P.0.35; see Figure 3) nor for NE (r=20.14 and 20.04; both
P.0.60). The correlation coefficients for both wake-associated
surges in systolic and diastolic blood pressure with E (both
P,0.04) differed significantly between normotensives and
hypertensives.
Discussion
The main result of the present study is that young participants
with mild newly diagnosed hypertension did not exhibit any strong
increase in NE and E levels during nocturnal sleep or during
preceding and succeeding 3-hour periods of wakefulness, in spite
of highly reliable differences in blood pressure. On a descriptive
level, hypertensives demonstrate even lower NE levels during
wakefulness before sleep as well as during sleep, although these
differences were not significant. During wakefulness in the
morning after sleep, E and NE levels were almost identical
between both groups, although increases in blood pressure from
sleep to wakefulness were distinctly stronger in the hypertensives.
Furthermore, whereas the morning increase in blood pressure
occurred in parallel with an increase in catecholamine levels in
normotensives, these parameters were completely unrelated in
hypertensives.
The lack of a strong increase in catecholamine concentrations in
our hypertensive participants stands in contrast with the common
view that sympathetic overdrive is responsible for the hypertensive
state and actively participates in its early development [1,4].
Several studies have reported increased plasma catecholamine
levels in hypertensive patients (see [1,20], for reviews), and direct
recordings from sympathetic nerve traffic to the vasculature have
revealed potentiated responses in hypertensive patients, suggesting
Figure 2. Heart rate, blood pressure and plasma catecholamines in 12 normotensive (thin line) and 12 hypertensive men (thick line)
during nocturnal sleep and a period of wakefulness of 3.5 hours before and after the sleep phase. Heart rate and blood pressure were
measured continuously, blood for the determination of catecholamines was drawn every 10 min during the sleep period. Profiles were averaged
across individuals and time locked to sleep onset and awakening in the morning, respectively. Bars indicate significant differences (P,0.05) for post
hoc comparison when ANOVA indicated overall significance for the factor condition (night-time vs. daytime sleep).
doi:10.1371/journal.pone.0021292.g002
Sleep, Catecholamines and Hyptertension
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21292that increased NE levels result from an enhanced vasoconstrictive
sympathetic drive [3,21]. This and further evidence have led to the
assumption that hypertension is a ‘‘hyperadrenergic state’’ [1,22].
However, those studies were almost exclusively performed in
waking subjects who often may not have been in a strictly
horizontal position. In the present study care was taken that
subjects were entirely relaxed an remained in a completely supine
position throughout the experimental period, leaving the possibil-
ity that the adrenergic overactivation seen in hypertensive patients
in previous studies depends on some additional orthostatic or
stress-related stimulation [19].
In contrast to the catecholamine levels, blood pressure was as
expected elevated in our hypertensive participants compared to the
normotensive controls throughout sleep and wakefulness. Impor-
tantly, blood pressure elevation in the hypertensives was most
pronounced during morning wakefulness after sleep, and this
elevation was not paralleled by any similar elevation of catechol-
amine levels in the hypertensive participants. Moreover, whereas in
the normotensive subjects the morning increase in blood pressure
was positively correlated with the increase in catecholamine levels,
mainly in epinephrine levels, no such correlation was found in the
hypertensive subjects. These results open the possibility that sleep-
related blood pressure regulation is dysfunctional in early
hypertension, with sympatho-adrenergic signaling exerting a
diminished control over blood pressure. The particular elevation
of blood pressure in hypertensives following morning awakening
being rather unrelated to concurrent adrenergic activity, might
originfromadisturbanceinsleepmechanismsspecifictothecontrol
of blood pressure, rather than from impaired sleep or sleep stages as
a whole, since sleep architecture in our hypertensive subjects was
similar to that in normotensive controls. Evidence for the notion of
an active control of waking blood pressure levels during previous
sleep has indeed been provided by a recent study that pharmaco-
logically prevented the reduction (‘dipping’) in blood pressure
during sleep by a continuous infusion of phenylephrine, an alpha-
adrenoceptoragonistthatdoesnotpasstheblood–brainbarrier[5].
The infusion significantly increased blood pressure during sleep,
with only minimal effects on sleep architecture and quality. The
disturbance of sleep-related dipping induced a strong counter-
regulation with a shift of the baroreflex threshold towards lower
blood pressure levels, which sustained for several hours during the
subsequent waking period. In our hypertensive subjects, reduced
dipping of blood pressure during sleep could have likewise
contributed to an exaggerated increase in blood pressure during
subsequent morning wakefulness. The present data add to those
previous findings in suggesting that, at least in early stages of
hypertension, blood pressure counter-regulation upon awakening
involve signals other than sympatho-adrenal activation.
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